NeoGenomics Raises Annual Guidance After Solid Q2 Earnings Beat
Portfolio Pulse from Nabaparna Bhattacharya
NeoGenomics, Inc. (NEO) reported Q2 revenues of $146.92 million, beating the consensus of $137.42 million. The company raised its FY23 revenues outlook to $565 million-$575 million, versus the consensus of $562.42 million. Despite the positive earnings report, NEO shares are down 2.88% at $15.35.
August 08, 2023 | 3:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
NeoGenomics reported better than expected Q2 revenues and raised its FY23 outlook. Despite this, its shares fell by 2.88%.
NeoGenomics reported strong Q2 results and raised its FY23 outlook, which would typically be expected to have a positive impact on the stock price. However, the stock price fell by 2.88%, suggesting that other factors may be influencing investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100